1. Less is More: Medicines that Require Less Frequent Administration Improve Adherence, but Are They Better?

   • Dyfrig Hughes

   Editorial 11 October 2012 Pages: 211 - 213

2. Aromatase Inhibitors in Breast Cancer

   • Jonathan Karnon

   Review Article 11 October 2012 Pages: 215 - 232

   

3. Trends in Outpatient Prescription Drug Use and Related Costs in the US

   • Diane K. Wysowski
   • Laura A. Governale
   • Joslyn Swann

   Short Communication 11 October 2012 Pages: 233 - 236

   

4. Cost Effectiveness of Extended Adjuvant Letrozole in Postmenopausal Women after Adjuvant Tamoxifen Therapy

   • Jonathan Karnon
   • Thomas Delea
   • Paul E. Goss

   Original Research Article 11 October 2012 Pages: 237 - 250

   

5. Cost Considerations in the Medical Management of Glaucoma in the US

   • Lawrence D. Goldberg
   • John Walt

   Original Research Article 11 October 2012 Pages: 251 - 264

   

6. Functional Impairment, Healthcare Costs and the Prevalence of Institutionalisation in Patients with Alzheimer’s Disease and Other Dementias

   • Jerrold Hill
   • Howard Fillit
   • Sobin Chang

   Original Research Article 11 October 2012 Pages: 265 - 280

   

7. Quality-of-Life Valuations of Advanced Breast Cancer by New Zealand Women

   • Richard J. Milne
   • Kathy H. Heaton-Brown
   • Alison Cubitt

   Original Research Article 11 October 2012 Pages: 281 - 292

   

8. Eliciting Social Preference Weights for Functional Assessment of Cancer Therapy-Lung Health States

   • A. Simon Pickard
   • Deborah Dobrez
   • David Cella

   Correspondence 11 October 2012 Pages: 293 - 294

   

9. The Authors’ Reply

   • Paul Kind
   • Sue Macran

   Correspondence 11 October 2012 Pages: 294 - 296

10. Bimatoprost

    • Greg L. Plosker
    • Susan J. Keam

    Adis Pharmacoeconomic Drug Evaluation 11 October 2012 Pages: 297 - 314